Weifa ASA (WEIFA)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Weifa ASA (WEIFA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012299
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ノルウェー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Weifa ASA (Weifa), formerly Aqualis ASA, is a pharmaceutical company that conducts the research and development, manufacture, distribution and sales of pharmaceutical products, lifestyle products and solutions. The company has over the counter (OTC) pharmaceutical market in Norway offering products for pain relief; treatment of cough and colds; dermatology; Nutraceuticals; dietary supplements; and wound treatment among others. Its research and development activities focus on prescription drug products, OTC products and nutraceuticals. It offers products to consumers, customers and professional partners. The company has operational presence in Denmark, Iceland, Sweden and Finland. Weifa is headquartered in Oslo, Norway.

Weifa ASA (WEIFA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Weifa ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Weifa ASA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Weifa ASA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Weifa ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Weifa ASA, Medical Devices Deals, 2011 to YTD 2017 9
Weifa ASA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Weifa ASA, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Weifa Enters into Licensing Agreement with AFT Pharma 11
Clavis Pharma Enters Into Licensing Agreement With Translational Therapeutics 12
Equity Offering 13
Weifa Raises USD13.6 Million in Private Placement of Shares 13
Aqualis to Raise USD116.7 Million in Private Placement of Shares 15
Aqualis to Raise USD16.7 Million in Rights Offering of Shares 16
Aqualis Completes Private Placement Of Shares For US$4 Million 17
Aqualis Completes Private Placement Of Shares For US$4.7 Million 18
Aqualis Completes Rights Offering Of Shares For US$9 Million 19
Debt Offering 20
Aqualis to Raise USD66.7 Million in Public Offering of Bonds 20
Acquisition 21
Karo Pharma Acquires Weifa 21
Aqualis Completes Acquisition of Weifa for USD183.6 Million 23
Weifa ASA – Key Competitors 24
Weifa ASA – Key Employees 25
Weifa ASA – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Jul 13, 2017: WEIFA: Record Second-Quarter Revenues Driven By Pain And Cough & Cold 27
Apr 27, 2017: Weifa: Record First-Quarter Revenues Driven by Organic Growth 28
Oct 25, 2016: Weifa: Record Third-Quarter Revenues and Growth for all Main Categories 29
Aug 25, 2016: Weifa: Second Quarter 2016 Results 30
Apr 26, 2016: Weifa: Record first-quarter revenues and proposed dividend 31
Product News 32
Oct 11, 2016: Weifa ASA to launch Ibux 200 mg soft capsules to strengthen its pain relief portfolio 32
Sep 14, 2016: Weifa to launch Solvivo – a new OTC product for sore throat in Norway 33
Other Significant Developments 34
Jun 06, 2016: Weifa: Distribution agreement in Finland for unique pain products 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Weifa ASA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Weifa ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Weifa ASA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Weifa ASA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Weifa ASA, Deals By Therapy Area, 2011 to YTD 2017 8
Weifa ASA, Medical Devices Deals, 2011 to YTD 2017 9
Weifa ASA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Weifa Enters into Licensing Agreement with AFT Pharma 11
Clavis Pharma Enters Into Licensing Agreement With Translational Therapeutics 12
Weifa Raises USD13.6 Million in Private Placement of Shares 13
Aqualis to Raise USD116.7 Million in Private Placement of Shares 15
Aqualis to Raise USD16.7 Million in Rights Offering of Shares 16
Aqualis Completes Private Placement Of Shares For US$4 Million 17
Aqualis Completes Private Placement Of Shares For US$4.7 Million 18
Aqualis Completes Rights Offering Of Shares For US$9 Million 19
Aqualis to Raise USD66.7 Million in Public Offering of Bonds 20
Karo Pharma Acquires Weifa 21
Aqualis Completes Acquisition of Weifa for USD183.6 Million 23
Weifa ASA, Key Competitors 24
Weifa ASA, Key Employees 25
Weifa ASA, Subsidiaries 26

★海外企業調査レポート[Weifa ASA (WEIFA)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Oilinvest (Netherlands) BV:企業の戦略的SWOT分析
    Oilinvest (Netherlands) BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Regis Corporation (RGS):企業の財務・戦略的SWOT分析
    Regis Corporation (RGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Ficosa International SA:企業の戦略・SWOT・財務情報
    Ficosa International SA - Strategy, SWOT and Corporate Finance Report Summary Ficosa International SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • National Real Estate Company K.S.C.:企業の戦略・SWOT・財務情報
    National Real Estate Company K.S.C. - Strategy, SWOT and Corporate Finance Report Summary National Real Estate Company K.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Empresas Publicas De Medellin ESP:企業の戦略的SWOT分析
    Empresas Publicas De Medellin ESP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Koken Co Ltd:企業の戦略的SWOT分析
    Koken Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Karolinska Development AB (KDEV):企業の財務・戦略的SWOT分析
    Summary Karolinska Development AB (Karolinska Development) is a life sciences investment company that develops innovations from science into commercial products. The company invests in start up's and growth of the pharmaceutical, medical device and biotechnology companies that develop specialty care …
  • Commercial Bank International PSC:企業の戦略・SWOT・財務情報
    Commercial Bank International PSC - Strategy, SWOT and Corporate Finance Report Summary Commercial Bank International PSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • The Charles Schwab Corporation:戦略・SWOT・企業財務分析
    The Charles Schwab Corporation - Strategy, SWOT and Corporate Finance Report Summary The Charles Schwab Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Singapore Press Holdings Ltd (T39):企業の財務・戦略的SWOT分析
    Singapore Press Holdings Ltd (T39) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Olvi plc:企業の戦略・SWOT・財務情報
    Olvi plc - Strategy, SWOT and Corporate Finance Report Summary Olvi plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • AMAG Pharmaceuticals Inc (AMAG)-医療機器分野:企業M&A・提携分析
    Summary AMAG Pharmaceuticals Inc (AMAG) is a biopharmaceutical company that develops and commercializes specialty pharmaceutical products. The company focuses on maternal health, anemia management and cancer supportive care. Its major products include Makena (hydroxyprogesterone caproate injection) …
  • Venus Remedies Ltd (VENUSREM):製薬・医療:M&Aディール及び事業提携情報
    Summary Venus Remedies Ltd (Venus) is a pharmaceutical company that develops, manufactures and commercializes research, herbal and generic products. The company’s manufactures products for analgesic and antipyretic, antibiotic, anticoagulant, disinfectant and antiseptic, iron supplement, neurology, …
  • Indianapolis Power & Light Co:電力:M&Aディール及び事業提携情報
    Summary Indianapolis Power & Light Co (IPL), a subsidiary of IPALCO Enterprises Inc, is an integrated electric utility. The company generates, transmits, distributes, and sells electric energy. It produces electricity from coal, oil, and natural gas sources. IPL owns and operates power plants in Ind …
  • Natera Inc (NTRA):企業の財務・戦略的SWOT分析
    Summary Natera Inc (Natera), formerly Gene Security Network Inc is a genetic testing and diagnostics company that develops and commercializes non-invasive methods for DNA analysis. The company offers Panorama, a non-invasive prenatal screening test that analyzes baby's DNA through a simple blood dra …
  • Moneygram International, Inc.:企業のM&A・事業提携・投資動向
    Moneygram International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Moneygram International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Aethlon Medical Inc (AEMD):企業の財務・戦略的SWOT分析
    Aethlon Medical Inc (AEMD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Duke Energy Carolinas LLC:企業の戦略的SWOT分析
    Duke Energy Carolinas LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Net One Systems Co Ltd (7518):企業の財務・戦略的SWOT分析
    Net One Systems Co Ltd (7518) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Global Tungsten & Powders Corp.:企業の戦略・SWOT・財務情報
    Global Tungsten & Powders Corp. - Strategy, SWOT and Corporate Finance Report Summary Global Tungsten & Powders Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆